Bal Pharma Limited (IN:BALPHARMA)

:BALPHARMA

BALPHARMA

Bal Pharma Limited

RESEARCH TOOLSreports

Bal Pharma Limited (BALPHARMA) Price & Analysis

0 Followers

BALPHARMA Stock Chart & Stats

₹73.91

-₹1.73(-1.42%)

At close: Jan 09 4:00 PM EST

₹73.91

-₹1.73(-1.42%)

Day’s Range― - ―

52-Week Range₹59.69 - ₹128.86

Previous CloseN/A

Volume11.87K

Average Volume (3M)4.08K

Market Cap

₹1.02B

Enterprise Value₹2.57B

Total Cash (Recent Filing)₹105.19M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)16.4

Beta0.51

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.62%

Share Statistics

EPS (TTM)1.12

Shares Outstanding15,920,872

10 Day Avg. Volume4,315

30 Day Avg. Volume4,084

Financial Highlights & Ratios

PEG Ratio-6.10

Price to Book (P/B)1.69

Price to Sales (P/S)0.43

P/FCF Ratio-9.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Business Model DiversificationBal Pharma's mix of finished dosage formulations and API manufacturing provides durable revenue diversification and vertical integration. In-house API capability and export exposure reduce customer concentration and support margin control and scalability across 2-6 months, aiding resilience to localized demand swings.

Stable Gross MarginsRelatively stable gross margins indicate the company sustains cost control at the production level, a durable operational strength. This stability cushions profitability against input price volatility and competitive pricing, supporting medium-term margin sustainability even if net margins face pressure.

Improving Return On EquityImproving ROE signals more efficient use of shareholder capital and potentially stronger operational profitability or capital allocation. If maintained, higher ROE can enhance retained earnings for reinvestment, supporting growth initiatives and shareholder value over the coming quarters.

Bears Say

High LeverageA high debt-to-equity ratio raises financial risk by increasing interest obligations and reducing flexibility for investment or downturns. Elevated leverage can strain cash flow, limit strategic options like capex or M&A, and magnify earnings volatility if sales weaken in the medium term.

Inconsistent Cash GenerationVolatile operating cash flow and episodes of negative free cash flow undermine the firm's ability to self-fund operations, service debt, and invest. Persistent cash-generation weakness increases reliance on external financing, raising refinancing and liquidity risk over the next several quarters.

Low Net Profit MarginLow net margins indicate that costs, interest, or inefficiencies erode revenue conversion to earnings. This constraint limits retained earnings for growth, makes the business sensitive to revenue shocks, and reduces capacity to absorb rising input or financing costs sustainably.

BALPHARMA FAQ

What was Bal Pharma Limited’s price range in the past 12 months?

Bal Pharma Limited lowest stock price was ₹59.69 and its highest was ₹128.86 in the past 12 months.

What is Bal Pharma Limited’s market cap?

Bal Pharma Limited’s market cap is ₹1.02B.

When is Bal Pharma Limited’s upcoming earnings report date?

Bal Pharma Limited’s upcoming earnings report date is Jun 01, 2026 which is in 57 days.

How were Bal Pharma Limited’s earnings last quarter?

Bal Pharma Limited released its earnings results on Feb 11, 2026. The company reported ₹1.118 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.118.

Is Bal Pharma Limited overvalued?

According to Wall Street analysts Bal Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bal Pharma Limited pay dividends?

Bal Pharma Limited pays a Annually dividend of ₹1.2 which represents an annual dividend yield of 1.62%. See more information on Bal Pharma Limited dividends here

What is Bal Pharma Limited’s EPS estimate?

Bal Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bal Pharma Limited have?

Bal Pharma Limited has 15,920,872 shares outstanding.

What happened to Bal Pharma Limited’s price movement after its last earnings report?

Bal Pharma Limited reported an EPS of ₹1.118 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.072%.

Which hedge fund is a major shareholder of Bal Pharma Limited?

Currently, no hedge funds are holding shares in IN:BALPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bal Pharma Limited

Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.